The outcome of COVID-19 in patients with hematological malignancy.

Abstract

In this study, we aim to report the outcomes for COVID‐19 in patients with hematological malignancy in Turkey. Data from laboratory‐confirmed 188 897 COVID‐19 patients diagnosed between 11 March 2020 and 22 June 2020 included in the Republic of Turkey, Ministry of Health database were analyzed retrospectively. All COVID‐19 patients with hematological malignancy (n = 740) were included in the study and an age, sex, and comorbidity‐matched cohort of COVID‐19 patients without cancer (n = 740) at a 1:1 ratio was used for comparison. Non‐Hodgkin lymphoma (30.1%), myelodysplastic syndrome (19.7%), myeloproliferative neoplasm (15.7%) were the most common hematological malignancies. The rates of severe and critical disease were significantly higher in patients with hematological malignancy compared with patients without cancer (P = .001). The rates of hospital and intensive care unit (ICU) admission were higher in patients with hematological malignancy compared with the patients without cancer (P = .023, P = .001, respectively). The length of hospital stay and ICU stay was similar between groups (P = .7, P = .3, retrospectively). The rate of mechanical ventilation (MV) support was higher in patients with hematological malignancy compared with the control group (P = .001). The case fatality rate was 13.8% in patients with hematological malignancy, and it was 6.8% in the control group (P = .001). This study reveals that there is an increased risk of COVID‐19‐related serious events (ICU admission, MV support, or death) in patients with hematological malignancy compared with COVID‐19 patients without cancer and confirms the high vulnerability of patients with hematological malignancy in the current pandemic.